New HIV med stands to boost J&J, Gilead by $500M

The newly minted combination HIV drug from Gilead Sciences and Johnson & Johnson, Complera, is expected to bring in more than $500 million annually. Release | Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.